Is Pertuzumab on the market?

In 2012, the U.S. Food and Drug Administration (FDA) first approved pertuzumab, along with docetaxel and another HER2-targeting monoclonal antibody, trastuzumab, for the treatment of metastatic HER2-positive breast cancer. Its indications have expanded to include use as neoadjuvant and adjuvant therapy in the treatment of HER2-positive breast cancer with a high risk of recurrence, but as of 2016, this use has not been shown to increase survival.

Pertuzumab’s active ingredientPertuzumab is a monoclonal antibody, a protein designed to attach to HER2, a protein found in her 2 Proteins found on positive cancer cells The loading dose of pertuzumab administered intravenously is 840 mg, followed by maintenance doses of 420 mg every 3 weeks, reaching steady-state concentrations after the first maintenance dose. Caution should be used when combining pertuzumab with anthracyclines. Women of childbearing age should use contraception while taking pertuzumab; it may harm the fetus of pregnant women, and it may be secreted into breast milk.

Pertuzumab is a strictly controlled drug. The original drug has been marketed in China and has entered the ranks of medical insurance, but it is only reimbursed for patients who meet the indications. The price of each box may be more than more than 5,000 yuan, and the price of the Hong Kong version may be more than 20,000 yuan (the price may fluctuate due to exchange rates). The price of each box of the European version of Pertuzumab's original drug marketed overseas may be more than 10,000 yuan, and the price of each box of the Turkish version may be more than 6,000 yuan (the price may fluctuate due to exchange rates). The ingredients of the domestic and foreign original drugs are basically the same, and there are currently no generic versions of Pertuzumab on the market.